Bristol-Myers Squibb Company
Bristol-Myers Squibb Company received $9.8M in federal prime contract obligations in the 12 months ending Oct 5, 2026, up 28.8% from $7.6M the year before, and $22.2M since FY2022. Its largest customer is the Department of Veterans Affairs.
See 5 contracts ending in the next 18 months ↓Contractor details
- Unique Entity ID (UEI)
- UFGKB2B71N12
- CAGE code
- 4K2D9
- Doing business as
- Bristol-Myers Squibb
- Headquarters
- Lawrenceville, NJ
- Business size
- Other Than Small Business
As recorded on this UEI's most recent prime contract action in USAspending.gov. Confirm current registration and certifications in SAM.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year.
Markets where it ranks top 10
Agency and NAICS markets where this UEI is one of the ten largest primes in the latest 12 months.
Top agencies
Funding agencies ranked by obligations since FY2022.
| Funding agency | Latest 12 mo | Since FY2022 |
|---|---|---|
| Department of Veterans Affairs | $9.8M | $22.1M |
| Department of Justice | $23K | $23K |
Top NAICS codes
Industry codes agencies recorded on this contractor's awards, since FY2022.
| NAICS | Industry | Latest 12 mo | Since FY2022 |
|---|---|---|---|
| 325412 | Pharmaceutical Preparation Manufacturing | $9.8M | $22.2M |
What it sells
Product and service codes (PSC) on this contractor's awards, since FY2022.
| PSC | Description | Since FY2022 |
|---|---|---|
| 6505 | Drugs and Biologicals | $22.1M |
| Q517 | Pharmacy Services | $23K |
Contracts ending in the next 18 months
This contractor's largest awards whose current period of performance ends soon. Options and extensions often move these dates.
| Award | Agency | Obligated | Current end |
|---|---|---|---|
| 36C25226N0198 | Department of Veterans Affairs REVLIMID, POMALYST, CAMZYOS SPECIALTY PHARMACEUTICALS | $848K | Oct 31, 2026 |
| 36C24926N0651 | Department of Veterans Affairs ABECMA INJECTION | $379K | Nov 9, 2026 |
| 36C24926N0658 | Department of Veterans Affairs BREYANZI INJECTION | $364K | Dec 14, 2026 |
| 36C24926N0433 | Department of Veterans Affairs BREAYNAZI FOR CAR-T TRANSPLANT MEDICATION | $364K | Jun 1, 2027 |
| 36C24527N0033 | Department of Veterans Affairs CAMZYOS AND POMALYST | $1.0M | Sep 30, 2027 |
Recent awards
This contractor's newest prime contract awards, most recent first.
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| 36C24527N0033 | Department of Veterans Affairs CAMZYOS AND POMALYST | $1.0M | Oct 1, 2026 |
| 36C24926N0651 | Department of Veterans Affairs ABECMA INJECTION | $379K | Aug 6, 2026 |
| 36C24926N0658 | Department of Veterans Affairs BREYANZI INJECTION | $364K | Aug 6, 2026 |
| 36C24526N0776 | Department of Veterans Affairs MAVACAMTEN (CAMZYOS) AND POMALIDOMIDE (POLMALYST) | $300K | Aug 2, 2026 |
| 36C24526N0790 | Department of Veterans Affairs POMALYST 2 MG, 3 MG,4 MG | $199K | Aug 2, 2026 |
| 36C24526N0785 | Department of Veterans Affairs POMALYST 4MG, CAMZYOS 2.5 MG | $51K | Aug 2, 2026 |
| 36C24526N0784 | Department of Veterans Affairs POMALYST 3 MG | $11K | Jul 31, 2026 |
| 36C24526N0740 | Department of Veterans Affairs POMALIDOMIDE(POMALYST) 4MG CAP | $16K | Jul 15, 2026 |
Prime contracts (award types A–D) from USAspending.gov through Oct 5, 2026. Subcontracts are not included. Net obligations include deobligations and corrections.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.